No Data
No Data
No Data
No Data
No Data
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Teladoc (TDOC) and Gilead Sciences (GILD)
TipRanksApr 26 19:50
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
Roivant And Kinevant Sciences Complete Enrollment In RESOLVE-Lung Phase 2 Study Evaluating Namilumab For Chronic Pulmonary Sarcoidosis
BenzingaApr 25 20:08
Critical Insights From Roivant Sciences Analyst Ratings: What You Need To Know
7 analysts have expressed a variety of opinions on Roivant Sciences (NASDAQ:ROIV) over the past quarter, offering a diverse set of opinions from bullish to bearish.The following table encapsulates the
BenzingaApr 22 23:01
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
HC Wainwright & Co. : The Roivant Sciences (ROIV.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $18.00.
Zhitong FinanceApr 22 18:40
HC Wainwright & Co. Reiterates Buy on Roivant Sciences, Maintains $18 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price target.
BenzingaApr 22 18:34
Analysts Are Bullish on Top Healthcare Stocks: Reviva Pharmaceuticals Holdings (RVPH), Roivant Sciences (ROIV)
TipRanksApr 22 18:20
No Data
No Data